Founded by a distinguished team of researchers in physiology, bioengineering, and trauma care, KaloCyte is close to delivery to in-use condition their product ErythroMer -- a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or simply in short supply. Background: In Fall 2019, when a number of Washington University faculty with connections to the firm relocated to University of Maryland, Kalocyte moved operations to Baltimore MD. The firm's principals are working on development of a freeze-dried blood substitute - designated ErythroMer - that is reconstitutable and can be used in treatment of traumatic hemorrhage when banked blood is unavailable: in ambulances; military environments, developing world or when use of whole blood is undesirable e.g. during cardiac surgery and organ perfusion, ErythroMer⢠red cell substitute is human hemoglobin encapsulated in a synthetic polymer shell designed precisely to emulate red blood cell oxygen binding/release. The shell does not require donor cross-matching. The nanoparticle has prolonged lyophilized stability at room temperature, is transportable in simple packaging, and is amenable to facile reconstitution with water for immediate field administration. With the prototype having passed rigorous initial âproof of conceptâ testing in rodent animal models of hemorrhage and hypoxemia, the product under furtherdevelopment will not require refrigeration and can be carried by soldiers and medics for prolonged field c
